Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.

ABSTRACT

BACKGROUND: The safety of non-selective ß-blockers in patients with advanced cirrhosis has been questioned in recent years. It was hypothesised that there is a particular therapeutic window. However, the specific limits still need to be determined. AIM: To evaluate potential limits of the therapeutic window of non-selective ß-blocker therapy in patients with cirrhosis and ascites METHODS: The impact of non-selective ß-blockers on 28-day transplant-free survival was analysed in a cohort of 624 consecutive patients with decompensated cirrhosis and ascites. Three potential limits were investigated spontaneous bacterial peritonitis, acute-on-chronic liver failure, mean arterial blood pressure ≤ 82 and < 65 mm Hg. RESULTS: Treatment with non-selective ß-blockers was associated with a higher 28-day transplant-free survival in the overall cohort (hazard ratio 0.621; P = .035) as well as in patients with acute-on-chronic liver failure (hazard ratio 0.578; P = .031) and those with spontaneous bacterial peritonitis (hazard ratio 0.594; P = .073). In contrast, survival benefits were markedly attenuated in patients with a mean arterial blood pressure ≤ 82 mm Hg and completely lost in those with mean arterial blood pressure < 65 mm Hg (P = .536). In spontaneous bacterial peritonitis patients with a mean arterial blood pressure < 65 mm Hg non-selective ß-blocker treatment was associated with renal impairment. Of note, among those with a mean arterial blood pressure ≥ 65 mm Hg non-selective ß-blocker intake was consistently associated with superior transplant-free survival (hazard ratio 0.582; P = .029) irrespective of the presence of spontaneous bacterial peritonitis (hazard ratio 0.435; P = .028) or acute-on-chronic liver failure (hazard ratio 0.480 P = .034). CONCLUSIONS: Ascites, acute-on-chronic liver failure and spontaneous bacterial peritonitis do not limit the safe use of non-selective ß-blockers in patients with cirrhosis. Mean arterial blood pressure might represent a better indicator to determine the therapeutic window of non-selective ß-blocker treatment.